Correspondence 0001193125-23-010945 from Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619) (ELVN)
Enliven Therapeutics, Inc. (ELVN) (CIK 0001672619)
Date: Jan. 19, 2023 · CIK: 0001672619 · Accession: 0001193125-23-010945
AI Filing Summary & Sentiment
File numbers found in text: 333-268300
Show Raw Text
CORRESP 1 filename1.htm CORRESP Imara Inc. 1309 Beacon Street, Suite 300, Office 341 Brookline, MA 02446 January 19, 2023 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attention: Jenn Do Kevin Vaughn Lauren Hamill Tim Buchmiller Re: Imara Inc. Registration Statement on Form S-4 File No. 333-268300 Request for Acceleration Ladies and Gentlemen: Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, Imara Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-4 (File No. 333-268300), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern time on January 23, 2023, or as soon thereafter as practicable. Very truly yours, IMARA INC. By: /s/ Rahul D. Ballal, Ph.D. Name: Rahul D. Ballal, Ph.D. Title: President and Chief Executive Officer